

Charles Swanton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4454222/publications.pdf>

Version: 2024-02-01

293
papers

67,802
citations

1992

101
h-index

834

245
g-index

332
all docs

332
docs citations

332
times ranked

83166
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. <i>New England Journal of Medicine</i> , 2012, 366, 883-892.	27.0	6,769
2	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
3	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
4	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469.	12.6	2,445
5	The causes and consequences of genetic heterogeneity in cancer evolution. <i>Nature</i> , 2013, 501, 338-345.	27.8	1,969
6	Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. <i>Cell</i> , 2017, 168, 613-628.	28.9	1,957
7	Tracking the Evolution of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	27.0	1,786
8	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17009.	30.5	1,727
9	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	27.8	1,287
10	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. <i>Nature Genetics</i> , 2014, 46, 225-233.	21.4	1,103
11	Chromosomal instability drives metastasis through a cytosolic DNA response. <i>Nature</i> , 2018, 553, 467-472.	27.8	1,002
12	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	28.9	968
13	Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157.	329.8	965
14	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. <i>Science</i> , 2014, 346, 251-256.	12.6	962
15	Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution. <i>Cancer Cell</i> , 2015, 27, 15-26.	16.8	923
16	deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. <i>Genome Biology</i> , 2016, 17, 31.	8.8	917
17	Intratumor Heterogeneity: Evolution through Space and Time. <i>Cancer Research</i> , 2012, 72, 4875-4882.	0.9	844
18	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	16.8	827

#	ARTICLE	IF	CITATIONS
19	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020, 31, 745-759.	1.2	770
20	Cancer heterogeneity: implications for targeted therapeutics. <i>British Journal of Cancer</i> , 2013, 108, 479-485.	6.4	753
21	Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. <i>Science</i> , 2020, 370, 1339-1343.	12.6	735
22	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1009-1021.	10.7	716
23	Replication stress links structural and numerical cancer chromosomal instability. <i>Nature</i> , 2013, 494, 492-496.	27.8	694
24	Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , 2019, 567, 479-485.	27.8	639
25	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. <i>Cell</i> , 2018, 173, 581-594.e12.	28.9	609
26	Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , 2015, 21, 846-853.	30.7	604
27	Genetic prognostic and predictive markers in colorectal cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 489-499.	28.4	602
28	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. <i>Science Translational Medicine</i> , 2015, 7, 283ra54.	12.4	589
29	Metastasis as an evolutionary process. <i>Science</i> , 2016, 352, 169-175.	12.6	497
30	Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. <i>Lancet</i> , The, 2021, 397, 2331-2333.	13.7	490
31	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14.	28.9	485
32	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. <i>Cell</i> , 2018, 173, 595-610.e11.	28.9	472
33	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	16.8	448
34	Intratumor Heterogeneity: Seeing the Wood for the Trees. <i>Science Translational Medicine</i> , 2012, 4, 127ps10.	12.4	443
35	Resolving genetic heterogeneity in cancer. <i>Nature Reviews Genetics</i> , 2019, 20, 404-416.	16.3	443
36	Translational Implications of Tumor Heterogeneity. <i>Clinical Cancer Research</i> , 2015, 21, 1258-1266.	7.0	424

#	ARTICLE	IF	CITATIONS
37	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704.	21.4	423
38	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	27.6	400
39	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. <i>Cell</i> , 2018, 173, 611-623.e17.	28.9	398
40	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. <i>Cancer Discovery</i> , 2015, 5, 704-712.	9.4	392
41	Chromosomal Instability Confers Intrinsic Multidrug Resistance. <i>Cancer Research</i> , 2011, 71, 1858-1870.	0.9	391
42	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. <i>British Journal of Cancer</i> , 2010, 103, 1139-1143.	6.4	381
43	COVID-19: the case for health-care worker screening to prevent hospital transmission. <i>Lancet, The</i> , 2020, 395, 1418-1420.	13.7	368
44	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	1.6	362
45	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology, The</i> , 2019, 20, 518-530.	10.7	362
46	Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution. <i>Cancer Discovery</i> , 2014, 4, 175-185.	9.4	359
47	Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. <i>Lancet Oncology, The</i> , 2020, 21, 1035-1044.	10.7	359
48	Origins of lymphatic and distant metastases in human colorectal cancer. <i>Science</i> , 2017, 357, 55-60.	12.6	358
49	Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. <i>Cancer Cell</i> , 2007, 11, 498-512.	16.8	351
50	Tumour heterogeneity and the evolution of polyclonal drug resistance. <i>Molecular Oncology</i> , 2014, 8, 1095-1111.	4.6	347
51	Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. <i>Nature</i> , 1997, 390, 184-187.	27.8	338
52	Cancer chromosomal instability: therapeutic and diagnostic challenges. <i>EMBO Reports</i> , 2012, 13, 528-538.	4.5	332
53	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586.	14.3	323
54	Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 605-619.	28.4	303

#	ARTICLE	IF	CITATIONS
55	Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer. <i>Cancer Research</i> , 2011, 71, 3447-3452.	0.9	296
56	Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. <i>Annals of Oncology</i> , 2017, 28, 1448-1456.	1.2	283
57	Early stage NSCLC " challenges to implementing ctDNA-based screening and MRD detection. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 577-586.	27.6	281
58	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. <i>Nature Biotechnology</i> , 2016, 34, 1037-1045.	17.5	279
59	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
60	Determinants and clinical implications of chromosomal instability in cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 139-150.	27.6	272
61	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. <i>Cell</i> , 2019, 179, 219-235.e21.	28.9	270
62	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. <i>Cell</i> , 2021, 184, 2239-2254.e39.	28.9	260
63	Chromosomal instability determines taxane response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8671-8676.	7.1	244
64	Clinical Implications of Genomic Discoveries in Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 1864-1873.	27.0	235
65	Cell-cycle targeted therapies. <i>Lancet Oncology</i> , The, 2004, 5, 27-36.	10.7	230
66	Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy. <i>Cancer Discovery</i> , 2015, 5, 821-831.	9.4	227
67	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	27.8	221
68	The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel. <i>Cancer Cell</i> , 2007, 12, 514-527.	16.8	202
69	Cancer: Evolution Within a Lifetime. <i>Annual Review of Genetics</i> , 2014, 48, 215-236.	7.6	196
70	Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. <i>Lancet</i> , The, 2020, 396, e6-e7.	13.7	196
71	The Role of Aneuploidy in Cancer Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a028373.	6.2	189
72	Scientific consensus on the COVID-19 pandemic: we need to act now. <i>Lancet</i> , The, 2020, 396, e71-e72.	13.7	189

#	ARTICLE	IF	CITATIONS
73	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. <i>PLoS Biology</i> , 2014, 12, e1001906.	5.6	185
74	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. <i>Nature Medicine</i> , 2020, 26, 1054-1062.	30.7	181
75	Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. <i>Genome Biology</i> , 2014, 15, 453.	8.8	180
76	Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. <i>Nature Medicine</i> , 2019, 25, 517-525.	30.7	178
77	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	10.7	178
78	Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. <i>Nature Genetics</i> , 2020, 52, 283-293.	21.4	168
79	The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. <i>BMC Medicine</i> , 2017, 15, 133.	5.5	166
80	Tumor Evolution as a Therapeutic Target. <i>Cancer Discovery</i> , 2017, 7, 805-817.	9.4	158
81	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. <i>Oncologist</i> , 2010, 15, 390-404.	3.7	155
82	A comprehensive survey of the mutagenic impact of common cancer cytotoxics. <i>Genome Biology</i> , 2016, 17, 99.	8.8	150
83	SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. <i>Oncogene</i> , 2015, 34, 5699-5708.	5.9	147
84	Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. <i>Nature Medicine</i> , 2019, 25, 1549-1559.	30.7	147
85	Prioritizing targets for precision cancer medicine. <i>Annals of Oncology</i> , 2014, 25, 2295-2303.	1.2	146
86	Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. <i>Nature Medicine</i> , 2019, 25, 1534-1539.	30.7	146
87	Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. <i>EMBO Journal</i> , 1999, 18, 654-663.	7.8	141
88	Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2183-2194.	2.5	141
89	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. <i>European Urology</i> , 2014, 66, 936-948.	1.9	141
90	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. <i>Genome Biology</i> , 2016, 17, 185.	8.8	140

#	ARTICLE	IF	CITATIONS
91	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	9.4	139
92	Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 862-867.	1.2	137
93	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet, The</i> , 2016, 388, 1002-1011.	13.7	132
94	Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. <i>Acta Oncologica</i> , 2006, 45, 196-201.	1.8	131
95	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	16.8	126
96	Kidney cancer: The next decade. <i>Journal of Experimental Medicine</i> , 2018, 215, 2477-2479.	8.5	125
97	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	13.2	123
98	The function and dysfunction of memory CD8 ⁺ T cells in tumor immunity. <i>Immunological Reviews</i> , 2018, 283, 194-212.	6.0	121
99	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , 2016, 13, e1002204.	8.4	119
100	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. <i>Annals of Oncology</i> , 2018, 29, 30-35.	1.2	118
101	Cancer evolution: Darwin and beyond. <i>EMBO Journal</i> , 2021, 40, e108389.	7.8	118
102	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. <i>Annals of Oncology</i> , 2013, 24, 647-654.	1.2	117
103	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. <i>Lancet Oncology, The</i> , 2010, 11, 358-365.	10.7	116
104	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	21.4	112
105	AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. <i>Lancet, The</i> , 2021, 398, 207-209.	13.7	112
106	Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. <i>Cell Reports</i> , 2020, 30, 481-496.e6.	6.4	111
107	Anthracycline cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 791-809.	2.4	108
108	Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. <i>Annals of Oncology</i> , 2018, 29, 271-279.	1.2	106

#	ARTICLE	IF	CITATIONS
109	89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 3945-3954.	7.0	105
110	Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy. <i>Cell Cycle</i> , 2009, 8, 3262-3266.	2.6	101
111	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015, 6, 6336.	12.8	100
112	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. <i>European Urology</i> , 2015, 67, 729-737.	1.9	100
113	Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. <i>Oncogene</i> , 2017, 36, 746-755.	5.9	98
114	Neoantigen quality, not quantity. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	98
115	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812.	27.8	96
116	HELO promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis. <i>Nature</i> , 2013, 502, 381-384.	27.8	94
117	Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. <i>Journal of Pathology</i> , 2013, 231, 424-432.	4.5	93
118	The centriolar satellite protein Cep131 is important for genome stability.. <i>Journal of Cell Science</i> , 2012, 125, 4770-9.	2.0	92
119	Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. <i>Journal of Pathology</i> , 2012, 227, 146-156.	4.5	92
120	APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. <i>Cancer Discovery</i> , 2017, 7, 218-233.	9.4	87
121	A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. <i>Breast Cancer Research</i> , 2013, 15, R110.	5.0	86
122	BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. <i>Cancer Cell</i> , 2017, 31, 79-93.	16.8	83
123	Three-dose vaccination elicits neutralising antibodies against omicron. <i>Lancet, The</i> , 2022, 399, 715-717.	13.7	82
124	Parallel evolution of tumour subclones mimics diversity between tumours. <i>Journal of Pathology</i> , 2013, 230, 356-364.	4.5	79
125	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. <i>Annals of Oncology</i> , 2016, 27, 1443-1448.	1.2	79
126	AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. <i>Nature</i> , 2021, 592, 799-803.	27.8	78

#	ARTICLE	IF	CITATIONS
127	Tracking Cancer Evolution through the Disease Course. <i>Cancer Discovery</i> , 2021, 11, 916-932.	9.4	77
128	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. <i>Nature Communications</i> , 2021, 12, 5606.	12.8	76
129	A clonal expression biomarker associates with lung cancer mortality. <i>Nature Medicine</i> , 2019, 25, 1540-1548.	30.7	75
130	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. <i>Cancer Discovery</i> , 2021, 11, 2456-2473.	9.4	74
131	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. <i>Nature Cancer</i> , 2020, 1, 546-561.	13.2	74
132	Chromosomal Instability, Colorectal Cancer and Taxane Resistance. <i>Cell Cycle</i> , 2006, 5, 818-823.	2.6	73
133	Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. <i>Lancet, The</i> , 2021, 398, 1038-1041.	13.7	73
134	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. <i>European Journal of Cancer</i> , 2010, 46, 2166-2177.	2.8	71
135	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 1362-1366.	30.7	70
136	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. <i>Genome Biology</i> , 2014, 15, 433.	8.8	69
137	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1935-1947.	1.1	69
138	Molecular classification of solid tumours: towards pathway-driven therapeutics. <i>British Journal of Cancer</i> , 2009, 100, 1517-1522.	6.4	68
139	Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER+ Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4853-4863.	0.9	66
140	Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. <i>Nature Communications</i> , 2021, 12, 1751.	12.8	66
141	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	13.2	66
142	Consequences of COVID-19 for cancer care – a CRUK perspective. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 3-4.	27.6	65
143	Genomic instability in mutant p53 cancer cells upon entotic engulfment. <i>Nature Communications</i> , 2018, 9, 3070.	12.8	64
144	Her2-Targeted Therapies in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4377s-4383s.	7.0	63

#	ARTICLE	IF	CITATIONS
145	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e141-e149.	3.8	63
146	The evolution of the unstable cancer genome. Current Opinion in Genetics and Development, 2014, 24, 61-67.	3.3	62
147	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	1.9	62
148	Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. Gastroenterology, 2021, 161, 1179-1193.	1.3	62
149	Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Annals of Oncology, 2015, 26, 1340-1346.	1.2	61
150	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications, 2020, 11, 3800.	12.8	61
151	Cancer Evolution Constrained by the Immune Microenvironment. Cell, 2017, 170, 825-827.	28.9	60
152	Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. Cancer Discovery, 2020, 10, 1489-1499.	9.4	60
153	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet, The, 2022, 399, 905-907.	13.7	60
154	Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics. Biochemical Pharmacology, 2012, 83, 1013-1020.	4.4	59
155	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026617.	6.2	59
156	A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. Journal of Pathology, 2012, 227, 29-41.	4.5	58
157	The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Annals of Oncology, 2015, 26, 2464-2469.	1.2	58
158	Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nature Communications, 2017, 8, 1773.	12.8	54
159	Implications of intratumour heterogeneity for treatment stratification. Journal of Pathology, 2014, 232, 264-273.	4.5	53
160	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. Nature Reviews Urology, 2012, 9, 147-155.	3.8	51
161	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
162	Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer. Oncologist, 2011, 16, 1535-1546.	3.7	50

#	ARTICLE	IF	CITATIONS
163	SnapShot: Renal Cell Carcinoma. <i>Cell</i> , 2015, 163, 1556-1556.e1.	28.9	50
164	Selection of metastasis competent subclones in the tumour interior. <i>Nature Ecology and Evolution</i> , 2021, 5, 1033-1045.	7.8	50
165	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. <i>Cancer Cell</i> , 2022, 40, 114-116.	16.8	50
166	TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. <i>BMC Medical Genomics</i> , 2015, 8, 58.	1.5	49
167	Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 402-402.	1.6	49
168	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e141-e149.	3.8	49
169	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploidâ€specific cancer cell death through autophagy induction. <i>Journal of Pathology</i> , 2012, 226, 482-494.	4.5	48
170	Taxane benefit in breast cancerâ€a role for grade and chromosomal stability. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 357-364.	27.6	48
171	Inferring mutational timing and reconstructing tumour evolutionary histories. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 264-275.	7.4	48
172	Breast cancer genome heterogeneity: a challenge to personalised medicine?. <i>Breast Cancer Research</i> , 2011, 13, 104.	5.0	46
173	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. <i>Annals of Oncology</i> , 2017, 28, 2472-2480.	1.2	45
174	Targeting chromosomal instability and tumour heterogeneity in HER2â€positive breast cancer. <i>Journal of Cellular Biochemistry</i> , 2010, 111, 782-790.	2.6	44
175	Intratumor heterogeneity reflects clinical disease course. <i>Nature Cancer</i> , 2020, 1, 3-6.	13.2	44
176	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	7.0	44
177	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. <i>Genome Medicine</i> , 2010, 2, 53.	8.2	43
178	Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2012, 56, 877-885.	3.7	43
179	Cyclin D mediates tolerance of genome-doubling in cancers with functional p53. <i>Annals of Oncology</i> , 2017, 28, 149-156.	1.2	43
180	Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020, 11, 2189.	12.8	43

#	ARTICLE	IF	CITATIONS
181	Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products. <i>International Journal of Experimental Pathology</i> , 2001, 82, 3-13.	1.3	42
182	New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , 2015, 24, 321-330.	2.2	42
183	Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. <i>ELife</i> , 2021, 10, .	6.0	42
184	Modelling the evolution of genetic instability during tumour progression. <i>Evolutionary Applications</i> , 2013, 6, 20-33.	3.1	41
185	Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution. <i>American Journal of Pathology</i> , 2013, 182, 1962-1971.	3.8	40
186	Re-Evaluating Clonal Dominance in Cancer Evolution. <i>Trends in Cancer</i> , 2016, 2, 263-276.	7.4	39
187	A local human V β 1 T cell population is associated with survival in nonsmall-cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 696-709.	13.2	39
188	FKBP1 Regulates Estrogen Receptor Signaling and Determines Response to Endocrine Therapy. <i>Cancer Research</i> , 2010, 70, 1090-1100.	0.9	38
189	Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. <i>Genome Medicine</i> , 2013, 5, 101.	8.2	38
190	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. <i>Neuro-Oncology</i> , 2017, 19, 1058-1067.	1.2	38
191	The translational challenges of precision oncology. <i>Cancer Cell</i> , 2022, 40, 458-478.	16.8	38
192	Tumour heterogeneity and immune-modulation. <i>Current Opinion in Pharmacology</i> , 2013, 13, 497-503.	3.5	37
193	Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. <i>Annals of Oncology</i> , 2015, 26, 880-887.	1.2	37
194	RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress. <i>Oncogene</i> , 2016, 35, 4009-4019.	5.9	37
195	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	27.8	36
196	Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. <i>Nature Communications</i> , 2021, 12, 5906.	12.8	36
197	Ccdc13; a novel human centriolar satellite protein required for ciliogenesis and genome stability. <i>Journal of Cell Science</i> , 2014, 127, 2910-9.	2.0	35
198	A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 1754-1773.	9.4	35

#	ARTICLE	IF	CITATIONS
199	Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. <i>Lancet</i> , The, 2022, 399, 800-802.	13.7	35
200	<scp>LRIG1</scp> regulates cadherinâ€dependent contact inhibition directing epithelial homeostasis and preâ€invasive squamous cell carcinoma development. <i>Journal of Pathology</i> , 2013, 229, 608-620.	4.5	34
201	How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2015, 25, 358-366.	1.8	34
202	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. <i>Journal of Experimental Medicine</i> , 2018, 215, 2748-2759.	8.5	34
203	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. <i>Cancer Discovery</i> , 2022, 12, 654-669.	9.4	34
204	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. <i>Nature Communications</i> , 2020, 11, 4527.	12.8	32
205	Scalable and robust SARS-CoV-2 testing in an academic center. <i>Nature Biotechnology</i> , 2020, 38, 927-931.	17.5	32
206	Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 523-546.	4.1	31
207	Cancer evolution: the final frontier of precision medicine?. <i>Annals of Oncology</i> , 2014, 25, 549-551.	1.2	31
208	Can oncology recapitulate paleontology? Lessons from species extinctions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 273-285.	27.6	31
209	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. <i>Nature Biotechnology</i> , 2022, 40, 1624-1633.	17.5	31
210	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. <i>Nature Ecology and Evolution</i> , 2022, 6, 88-102.	7.8	30
211	Constraints in cancer evolution. <i>Biochemical Society Transactions</i> , 2017, 45, 1-13.	3.4	29
212	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. <i>Current Cancer Drug Targets</i> , 2010, 10, 799-812.	1.6	28
213	Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 127-134.	3.8	28
214	Analysis of intratumor heterogeneity unravels lung cancer evolution. <i>Molecular and Cellular Oncology</i> , 2015, 2, e985549.	0.7	28
215	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. <i>PLoS Medicine</i> , 2016, 13, e1002136.	8.4	28
216	Implications of cancer evolution for drug development. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 441-442.	46.4	28

#	ARTICLE	IF	CITATIONS
217	Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. <i>Open Biology</i> , 2021, 11, 200247.	3.6	28
218	The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e56707.	2.5	28
219	Cancer heterogeneity and "The Struggle for Existence": Diagnostic and analytical challenges. <i>Cancer Letters</i> , 2013, 340, 220-226.	7.2	26
220	Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status. <i>PLoS ONE</i> , 2010, 5, e15031.	2.5	26
221	The Genome of the Chicken DT40 Bursal Lymphoma Cell Line. <i>G3: Genes, Genomes, Genetics</i> , 2014, 4, 2231-2240.	1.8	25
222	The future of UK healthcare: problems and potential solutions to a system in crisis. <i>Annals of Oncology</i> , 2017, 28, 1751-1755.	1.2	25
223	Cancer Research: The Lessons to Learn from COVID-19. <i>Cancer Discovery</i> , 2020, 10, 1263-1266.	9.4	25
224	Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. <i>Nature Communications</i> , 2020, 11, 1792.	12.8	25
225	Overcoming inhibitions: subversion of CKI function by viral cyclins. <i>Trends in Biochemical Sciences</i> , 1999, 24, 116-120.	7.5	24
226	Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. <i>EPMA Journal</i> , 2012, 3, 3.	6.1	23
227	Spatial and temporal cancer evolution: causes and consequences of tumour diversity. <i>Clinical Medicine</i> , 2014, 14, s33-s37.	1.9	23
228	Chromosomal Instability, Aneuploidy, and Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 161.	2.8	23
229	Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?. <i>Frontiers in Oncology</i> , 2012, 2, 49.	2.8	22
230	Cancer Evolution Constrained by Mutation Order. <i>New England Journal of Medicine</i> , 2015, 372, 661-663.	27.0	22
231	Evolving adoptive cellular therapies in urological malignancies. <i>Lancet Oncology</i> , The, 2017, 18, e341-e353.	10.7	22
232	Prospective analysis of 895 patients on a UK Genomics Review Board. <i>ESMO Open</i> , 2019, 4, e000469.	4.5	22
233	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	9.6	21
234	Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, 214.	5.0	20

#	ARTICLE	IF	CITATIONS
235	Computational optimisation of targeted DNA sequencing for cancer detection. <i>Scientific Reports</i> , 2013, 3, 3309.	3.3	20
236	Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. <i>Cancer Research</i> , 2014, 74, 2946-2961.	0.9	20
237	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. <i>Annual Review of Cancer Biology</i> , 2017, 1, 223-240.	4.5	20
238	Securing the future of the clinician-scientist. <i>Nature Cancer</i> , 2020, 1, 139-141.	13.2	20
239	Capturing cancer evolution using genetically engineered mouse models (GEMMs). <i>Trends in Cell Biology</i> , 2021, 31, 1007-1018.	7.9	20
240	A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms. <i>Mutagenesis</i> , 2021, 36, 75-86.	2.6	19
241	Take lessons from cancer evolution to the clinic. <i>Nature</i> , 2020, 581, 382-383.	27.8	19
242	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. <i>EPMA Journal</i> , 2012, 3, 1.	6.1	18
243	International cancer seminars: a focus on kidney cancer. <i>Annals of Oncology</i> , 2016, 27, 1382-1385.	1.2	18
244	Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors. <i>International Journal of Cancer</i> , 2018, 143, 160-166.	5.1	18
245	Targeting Polo-Like Kinase: Learning Too Little Too Late?. <i>Journal of Clinical Oncology</i> , 2008, 26, 5497-5499.	1.6	17
246	From genomic landscapes to personalized cancer management—is there a roadmap?. <i>Annals of the New York Academy of Sciences</i> , 2010, 1210, 34-44.	3.8	16
247	Quantification of tumour evolution and heterogeneity via Bayesian epiallele detection. <i>BMC Bioinformatics</i> , 2017, 18, 354.	2.6	15
248	An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood. <i>Methods in Molecular Biology</i> , 2019, 1884, 15-42.	0.9	15
249	Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs. <i>Cell Cycle</i> , 2007, 6, 2001-2004.	2.6	14
250	Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 639-649.	2.4	14
251	The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. <i>Cancer Discovery</i> , 2017, 7, 796-798.	9.4	14
252	Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy. <i>Cancer Discovery</i> , 2016, 6, 122-124.	9.4	13

#	ARTICLE	IF	CITATIONS
253	Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 127-134.	3.8	13
254	Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics. Cancer Cell, 2008, 13, 83-85.	16.8	12
255	Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs, 2011, 71, 2099-2113.	10.9	12
256	Epigenetic Noise Fuels Cancer Evolution. Cancer Cell, 2014, 26, 775-776.	16.8	12
257	Evolutionary dynamics in pre-invasive neoplasia. Current Opinion in Systems Biology, 2017, 2, 1-8.	2.6	12
258	RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?. Lancet Oncology, The, 2004, 5, 653-654.	10.7	11
259	A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. British Journal of Cancer, 2010, 103, 607-612.	6.4	11
260	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. Genome Biology, 2014, 15, 470.	8.8	11
261	Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy and Behavior, 2021, 115, 107602.	1.7	11
262	Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 221-229.	2.5	10
263	Promoting predictive, preventive and personalised medicine: European event of global importance. EPMA Journal, 2011, 2, 131-136.	6.1	9
264	Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in <i>ALK</i> -Rearranged Lung Adenocarcinoma?. Journal of Clinical Oncology, 2015, 33, 3681-3683.	1.6	9
265	Environmental emissions, public health and lung cancer risk. Annals of Oncology, 2016, 27, 211-212.	1.2	9
266	Review: Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2009, 1, 15-27.	3.2	8
267	SAFIR01: steps towards precision treatment in breast cancer. Lancet Oncology, The, 2014, 15, 242-243.	10.7	8
268	Cancer therapeutics through an evolutionary lens. Journal of the Royal Society of Medicine, 2018, 111, 8-14.	2.0	8
269	A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget, 2011, 2, 529-537.	1.8	8
270	CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. Science Translational Medicine, 2022, 14, .	12.4	8

#	ARTICLE	IF	CITATIONS
271	Cellular Prion Protein PrPC and Ecto-5â€²-Nucleotidase Are Markers of the Cellular Stress Response to Aneuploidy. <i>Cancer Research</i> , 2017, 77, 2914-2926.	0.9	7
272	Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities. <i>Cancer Research</i> , 2022, 82, 1589-1602.	0.9	7
273	RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e15.	3.9	6
274	Plasma-Derived Tumor DNA Analysis at Whole-Genome Resolution. <i>Clinical Chemistry</i> , 2013, 59, 6-8.	3.2	6
275	A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 691-698.	2.5	6
276	Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 971-972.	1.6	6
277	Combined inhibition of BRAF and MEK in melanoma patients. <i>Lancet Oncology</i> , The, 2014, 15, 908-910.	10.7	6
278	Tetraploidy and CIN: a dangerous combination. <i>Cell Cycle</i> , 2015, 14, 3217-3217.	2.6	6
279	KRAS 3â€²-UTR variants and stratification of breast-cancer risk. <i>Lancet Oncology</i> , The, 2011, 12, 318-319.	10.7	5
280	Understanding the impact of immune-mediated selection on lung cancer evolution. <i>British Journal of Cancer</i> , 2021, 124, 1615-1617.	6.4	5
281	Tracking tumour evolution through liquid biopsy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 565-566.	27.6	4
282	Protecting â€œcovid protectedâ€•cancer hubs. <i>BMJ</i> , The, 2020, 369, m2062.	6.0	4
283	Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure. <i>Cell Cycle</i> , 2008, 7, 3947-3948.	2.6	3
284	Relapse models for clear cell renal carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e376-e378.	10.7	3
285	E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. <i>Oncogene</i> , 2021, 40, 5567-5578.	5.9	3
286	Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. <i>EPMA Journal</i> , 2012, 3, 6.	6.1	2
287	Multidisciplinary urological engagement in translational renal cancer research. <i>BJU International</i> , 2014, 114, 474-475.	2.5	2
288	Response to Bakhoun et al.. <i>Current Biology</i> , 2014, 24, R150.	3.9	2

#	ARTICLE	IF	CITATIONS
289	Reply to J.J. Tao et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2451-2451.	1.6	1
290	<i>Principles of Targeted and Biological Therapies.</i> , 2006, , 73-90.		0
291	<i>Chemotherapy and metastatic breast cancer.</i> , 2011, , 67-92.		0
292	The centriolar satellite protein Cep131 is important for genome stability. <i>Development (Cambridge)</i> , 2013, 140, e207-e207.	2.5	0
293	APOBEC3 as a driver of genetic intratumor heterogeneity. <i>Molecular and Cellular Oncology</i> , 0, , .	0.7	0